OncoMatch/Clinical Trials/NCT05948475
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Is NCT05948475 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tinengotinib 8 mg and Tinengotinib 10 mg for cholangiocarcinoma.
Treatment: Tinengotinib 8 mg · Tinengotinib 10 mg · Physician's Choice — This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: FGFR2 fusion/rearrangement
Prior therapy
Must have received: chemotherapy
Subjects must have received at least one line of prior chemotherapy
Must have received: FGFR inhibitor
exactly one FDA approved FGFR inhibitor
Cannot have received: FGFR inhibitor
Prior receipt of two or more FGFR inhibitors, either approved or investigational drugs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA Medical Center · Santa Monica, California
- Stanford Cancer Center · Stanford, California
- The University of Kansas Cancer Center · Westwood, Los Angeles, California
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- The University of Chicago Hospitals · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify